oncgnostics GmbH
The company, rebranded from oncgnostics GmbH to Epitype GmbH in 2025, develops molecular biological in-vitro diagnostic tests for cancer screening and diagnosis. Its primary products, GynTect and ScreenYu Gyn, utilize patented epigenetic biomarkers to identify cervical cancer and its precursors. These tests are designed for use in diagnostic laboratories to assist in early detection and clinical decision-making.
Biotechnology
Diagnostics
Healthtech
Funding summary
- Total raised
- €1.0M
- Funding rounds
- 2
Investors in oncgnostics GmbH
Investors on record for oncgnostics GmbH. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like oncgnostics GmbH?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors